Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | KCNQ3 | O43525 | 2/20 | 0.42 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.42 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.42 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1280272 | 0.84 | HPGD (0.57) | ALDH1A1AGTR1KDM4EHPGDMAPT | |
| SCHEMBL31114440 | 0.84 | CES2 (0.53) | HPGDRAB9ALMNAMAPK1HTT | |
| SCHEMBL10780708 | 0.84 | RAB9A (0.46) | SLC6A4KCNQ3KCNQ2KCNE1KCNQ1 | |
| SCHEMBL20703151 | 0.84 | ALDH1A1 (0.49) | KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1 | |
| SCHEMBL5449312 | 0.81 | HDAC1 (0.53) | KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1 | |
| SCHEMBL18538090 | 0.81 | MAPT (0.54) | KCNQ3KCNQ2KCNE1KCNQ1ALDH1A1 | |
| SCHEMBL6559766 | 0.80 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL30467135 | 0.80 | KCNQ3 (0.47) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL16563526 | 0.80 | SLC6A4 (0.44) | SLC6A4ALDH1A1RAB9ALMNAMAPK1 | |
| SCHEMBL3502522 | 0.79 | KCNQ3 (0.46) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420679-B2 | Aminothiazole derivatives and their use as CRF receptor ligands | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | SANOFI-AVENTIS (FR) | 2007-12-06 | — | — | US | disclosed |
| EP-1200419-B1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI SYNTHELABO (FR) | 2004-04-14 | — | — | EP | disclosed |
| US-6586456-B1 | Corticotropin releasing factor (CRF) antagonists such as (4-(2-chloro-4-methoxy-5-methylphenyl)-5-methylthiazol-2-yl)(( (1-(3-fluoro-4-methylphenyl)-2-methoxyethyl))prop-2-ynylamine, prepared by alkylation with propagyl bromide | SANOFI-SYNTHELABO (FR) | 2003-07-01 | — | — | US | disclosed |
| EP-1200419-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001005776-A1 | AMINOTHIAZOLE DERIVATIVES AND THEIR USE AS CRF RECEPTOR LIGANDS | SANOFI-SYNTHELABO (FR) | 2001-01-25 | — | — | WO | disclosed |
| EP-0188194-B1 | AMINOACRYLIC ACID DERIVATIVES | BAYER AG (DE) | 1990-07-04 | — | — | EP | disclosed |
| US-4695646-A | OXYQUINOLINECARBOXYLIC ACID INTERMEDIATES | BAYER AKTIENGESELLSCHAFT (DE) | 1987-09-22 | — | — | US | disclosed |
| EP-0188194-A2 | Aminoacrylic acid derivatives | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281919-A1 | Aminothiazole Derivatives And Their Use As CRF Receptor Ligands | CRH, CRHR1, CRHR2 | SLC6A4 175/4885KCNQ3 3595/4885KCNQ2 3382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.